- Conditions
- Prostate Adenocarcinoma
- Interventions
- Flibanserin 100 MG, Placebo, Androgen deprivation therapy
- Drug
- Lead sponsor
- Andrew McDonald
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 307
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Prostate Cancer
- Interventions
- Naltrexone
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Prostatic Neoplasm
- Interventions
- AAA617, AAA517, Piflufolastat F 18, ARPI, ADT, Best supportive care
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 10
- States / cities
- Denver, Colorado • Athens, Georgia • Indianapolis, Indiana + 7 more
- Conditions
- Elderly, Prostate Cancer
- Interventions
- LHRH Agonist Therapy Discontinuation
- Behavioral
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 70 Years and older · Male only
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Adenocarcinoma of the Prostate
- Interventions
- Radiation Therapy, Androgen Deprivation Therapy (ADT)
- Radiation · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2025
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland
- Conditions
- Prostate Cancer, Hot Flashes
- Interventions
- VMS logging
- Behavioral
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Prostate Cancer, Osteoporosis, Fractures
- Interventions
- Toremifene Citrate
- Drug
- Lead sponsor
- GTx
- Industry
- Eligibility
- 50 Years and older · Male only
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 136
- States / cities
- Homewood, Alabama • Mobile, Alabama • Little Rock, Arkansas + 117 more
- Conditions
- Prostate Cancer
- Interventions
- Prostate Fossa Radiotherapy, Pelvic nodal Radiotherapy, Androgen Deprivation Therapy (ADT)
- Radiation · Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Prostate Cancer
- Interventions
- Bicalutamide, Leuprolide, Goserelin, Triptorelin, Docetaxel, Abiraterone, Apalutamide, Enzalutamide
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 21 Years to 85 Years · Male only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Prostate Cancer
- Interventions
- zoledronic acid
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 38 more
- Conditions
- Prostate Cancer, Cardiotoxicity, Drug-Related Side Effects and Adverse Reactions, Cardiovascular Diseases
- Interventions
- Social Determinants of Health
- Other
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- GnRH agonist, Anti-androgen, TAK-700, Radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 165
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 136 more
- Conditions
- Prostate Cancer
- Interventions
- Apalutamide, Placebo, Androgen Deprivation Therapy (ADT)
- Drug
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,052 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 39
- States / cities
- Homewood, Alabama • Tucson, Arizona • San Bernardino, California + 36 more
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Behavioral Dietary Intervention, Counseling, Educational Intervention, Exercise Intervention, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Quality-of-Life Assessment, Triptorelin Pamoate
- Behavioral · Other · Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Male only
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Stage IV Prostate Adenocarcinoma AJCC v7
- Interventions
- Antiandrogen Therapy, Docetaxel, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Radical Prostatectomy
- Drug · Other · Procedure
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 7
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 4 more
- Conditions
- Hypogonadism, Metabolic Syndrome, Diabetes, Inflammation
- Interventions
- Pioglitazone
- Drug
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Prostate Cancer
- Interventions
- CARE-PC Web-Based Application
- Behavioral
- Lead sponsor
- Vivek Narayan
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- Apalutamide, Androgen deprivation, Salvage radiation therapy, Docetaxel
- Drug · Radiation
- Lead sponsor
- Andrew J. Armstrong, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 5
- States / cities
- Omaha, Nebraska • New York, New York • Cary, North Carolina + 2 more
- Conditions
- Prostate Cancer
- Interventions
- Androgen Deprivation Therapy (ADT), Focal prostate ablation (focal therapy)
- Drug · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Prostate Cancer
- Interventions
- Pembrolizumab, Olaparib, Androgen Deprivation Therapy, Radiation Therapy
- Biological · Drug · Radiation
- Lead sponsor
- Zin W Myint
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 2
- States / cities
- Lexington, Kentucky • Salt Lake City, Utah
- Conditions
- Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium, Laparoscopic Radical Prostatectomy with Robotics, Pelvic Lymphadenectomy, Positron Emission Tomography, Relugolix
- Procedure · Other · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer
- Interventions
- BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel, Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 58
- States / cities
- Chandler, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
- Conditions
- Prostate Cancer
- Interventions
- myocardial PET imaging
- Device
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 51 Years and older · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Prostate Carcinoma
- Interventions
- Oxybutynin Chloride, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 103
- States / cities
- Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 77 more